Blueprint Medicines (BPMC) has issued an update.
At Blueprint Medicines Corporation’s 2024 Annual Meeting, shareholders backed key initiatives, including the adoption of the 2024 Stock Incentive Plan and the election of three Class III directors for a three-year term. Shareholders voted to hold annual advisory votes on executive compensation, approved the current executive pay, and ratified the appointment of Ernst & Young LLP as the independent auditor for the coming year. These decisions reflect shareholder engagement and support for the company’s strategic direction and governance practices.
Learn more about BPMC stock on TipRanks’ Stock Analysis page.
